Paul Hastings Represents BioMarin Pharmaceutical Inc. in $750 Million Offering of Convertible Notes

October 22, 2013
San Francisco, CA-- Paul Hastings LLP, a leading global law firm, announced today that it represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of $375,000,000 aggregate principal amount of its 0.75% Senior Subordinated Convertible Notes due 2018 and $375,000,000 aggregate principal amount of its 1.50% Senior Subordinated Convertible Notes due 2020.

BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Barclays acted as co-manager for the offering.

In connection with the pricing of the offering and the exercise in full of their overallotment option by the underwriters, BioMarin entered into privately-negotiated capped call transactions with Bank of America, N.A., Morgan Stanley & Co. LLC and Barclays Bank PLC in respect of 50% of the principal amount of the notes.

Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included partners Robert Claassen, Michael ZupponeLeigh Ryan and Andrew Short and associates Sasha Burstein, Peiyi Zhao, Christy Chen, Aliza CohenDaniel Greenwald and Kaethin Prizer. 

Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.